Ra Pharmaceuticals Inc

What indicators would you like to setup a trade for?

Candlestick Daily volume index Bar reversal Edit

Trade setup

Position Order Entry Exit Stop Loss Risk Return Expectancy
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%

What indicators would you like to backtest?

Candlestick Daily volume index Bar reversal Edit

Backtest results

Position Trades Duration Win rate Win/loss Avg win Avg loss Return
Long 10 4.5 20% 25% 1.6% -0.8% -3.4%
Short 5 4.2 40% 67% 1.9% -3.2% -5.9%



Code Company Date Close Change Indicator Value Signal

Trading Performance

Pivot Points



Position Trades Duration Win Rate Win/Loss Avg Win Avg Loss Return
LONG 130 3.9 0.38% 0.62% 4.4% -3.0% -25.1%
SHORT 130 3.6 0.38% 0.58% 3.1% -3.9% -179.1%


Technical Analysis

Ra Pharmaceuticals Inc (RARX)



Signal Strength: MEDIUM

Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading position.

Ra Pharmaceuticals Inc (NASDAQ:RARX) current pivot point is: $ 47.027.
The current resistance levels are:
(R1) $47.084
(R2) $47.177
(R3) $47.234

The current support levels are:
(S1) $46.934
(S2) $46.877
(S3) $46.784

Pivots Points are significant levels chartists can use to determine directional movement support and resistance. Pivot Points use the prior period’s high low and close to formulate future support and resistance. In this regard Pivot Points are predictive or leading indicators.

Calculation: Pivot Points:
1) Pivot Point (P) = (High + Low + Close)/3;
2) Support 1 (S1) = (P x 2) – High; Support 2 (S2) = P - (High - Low);
3) Resistance 1 (R1) = (P x 2) – Low Resistance 2; (R2) = P + (High - Low);

PROFILE: Ra Pharmaceuticals Inc (RARX)

Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |

About Ra Pharmaceuticals Inc (NASDAQ:RARX):

Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Top 10:

Pivot Points

Company Close Change(%) Volume Value Signal
IIIN Insteel Industries 26.01 6.9 349,900 -0.11 BEARISH CROSSOVER
NNBR Nn Inc 9.97 4.6 339,800 -0.29 BEARISH CROSSOVER
QCOM Qualcomm Inc 95.91 4.5 23,694,300 -1.13 BEARISH CROSSOVER
ATRC Atricure Inc 38.25 4.1 790,500 -0.02 BEARISH CROSSOVER
ELGX Endologix Inc 2.03 3.6 273,500 -0.01 BEARISH CROSSOVER
RUN Sunrun Inc 17.18 3.5 3,455,500 -0.18 BEARISH CROSSOVER
GBLI Global Indemnity Plc 30.7 3.2 13,100 -0.37 BEARISH CROSSOVER
PETS Petmed Express Inc 27.26 2.8 905,900 -0.19 BEARISH CROSSOVER
BCOM B Communications 1.61 2.5 700 -0.06 BEARISH CROSSOVER
MTSC MTS Systems 51.67 2.2 113,400 -0.07 BEARISH CROSSOVER